Michael Seckler
Directeur Général chez EVOME MEDICAL TECHNOLOGIES INC.
Fortune : - $ au 31/05/2024
Postes actifs de Michael Seckler
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Directeur/Membre du Conseil | 13/06/2023 | - |
| Directeur Général | 13/06/2023 | - | |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Michael Seckler
Anciens postes connus de Michael Seckler
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Directeur des opérations | 01/10/2022 | 01/05/2023 |
| Corporate Officer/Principal | 01/01/2020 | 01/10/2022 | |
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Sales & Marketing | 01/03/2003 | 01/12/2019 |
Formation de Michael Seckler
| The Pennsylvania State University | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
| Canada | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Sales & Marketing | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Michael Seckler
- Expérience
